Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Mersana Therapeutics Q2 2024 GAAP EPS $(0.20) Misses $(0.17) Estimate, Sales $2.293M Miss $8.722M Estimate

Author: Benzinga Newsdesk | August 13, 2024 07:03am
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.17) by 17.65 percent. The company reported quarterly sales of $2.293 million which missed the analyst consensus estimate of $8.722 million by 73.71 percent. This is a 78.48 percent decrease over sales of $10.654 million the same period last year.

Posted In: MRSN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist